Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Tianji 999" (or simply Tianji) is a trade brand utilized by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu) for its portfolio of specialty pharmaceutical products in China. The brand encompasses a diverse range of generic small molecule drugs across several therapeutic areas, most notably oncology, supportive care, cardiovascular medicine, and hepatology. Key products marketed under the Tianji label include **ondansetron hydrochloride** (a selective 5-HT3 receptor antagonist used as an antiemetic), **gefitinib** (an EGFR tyrosine kinase inhibitor for non-small cell lung cancer), **bicalutamide** (an androgen receptor antagonist for prostate cancer), **amlodipine besylate** (a calcium channel blocker for hypertension), and **entecavir** (a nucleoside analog for hepatitis B). The brand is particularly recognized for its oncology supportive care offerings, such as the orally disintegrating tablet formulation of ondansetron. Because the name refers to a commercial product line rather than a single chemical entity, its clinical application and mechanism of action are non-specific and depend on the specific medication within the Tianji portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tianji 999.